These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38505288)

  • 1. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort.
    Gao H; Wang J; Zheng X; Pei X; Zheng Y; Zhai W; Zhang R; Chen X; Ma Q; Wei J; Yang D; Pang A; He Y; Feng S; Cao Y; Jiang E
    Front Cell Infect Microbiol; 2024; 14():1324019. PubMed ID: 38505288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
    Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
    Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study.
    Hu L; Zhang H; Huang C; Shen T; Feng Z; Mu F; Xu L; Lin Y; Yue C; Guo K; Tian M; Shi J; Zhang C; Wen P; Cao S; Wang Y; Zhang J; Shi X; Wang Z; He Y; Zhang X; Liu X; Lv Y; Liu Z; Guo W; Wang B
    QJM; 2024 Jun; 117(5):339-347. PubMed ID: 37950449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
    Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M
    Front Immunol; 2023; 14():1169666. PubMed ID: 37153556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis.
    John BV; Bastaich D; Webb G; Brevini T; Moon A; Ferreira RD; Chin AM; Kaplan DE; Taddei TH; Serper M; Mahmud N; Deng Y; Chao HH; Sampaziotis F; Dahman B
    J Intern Med; 2023 May; 293(5):636-647. PubMed ID: 37018129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
    Piñana JL; López-Corral L; Martino R; Montoro J; Vazquez L; Pérez A; Martin-Martin G; Facal-Malvar A; Ferrer E; Pascual MJ; Sanz-Linares G; Gago B; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; López-Jimenez J; Marcos-Corrales S; García-Blázquez M; Garcia-Gutiérrez V; Hernández-Rivas JÁ; Saus A; Espigado I; Alonso C; Hernani R; Solano C; Ferrer-Lores B; Guerreiro M; Ruiz-García M; Muñoz-Bellido JL; Navarro D; Cedillo A; Sureda A;
    Am J Hematol; 2022 Jan; 97(1):30-42. PubMed ID: 34695229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study.
    Fan S; Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Zhang Y; Cheng Y; Sun Y; Chen Y; Chen Y; Han W; Wang J; Wang F; Xu Z; Huang X
    Ann Hematol; 2024 Apr; 103(4):1333-1344. PubMed ID: 38381172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC.
    Jondreville L; D'Aveni M; Labussière-Wallet H; Le Bourgeois A; Villate A; Berceanu A; Bezsera SM; Thiebaut A; Boissard-Simonet M; Legrand M; Cornillon J; Rubio MT; Chevallier P; Nguyen S
    J Hematol Oncol; 2022 Nov; 15(1):169. PubMed ID: 36443846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
    Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
    Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid administration did not reduce susceptibility to SARS-CoV-2 infection in children.
    Liu T; Wang JS
    Liver Int; 2023 Sep; 43(9):1950-1954. PubMed ID: 37381749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
    Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.
    Li Y; Zhu N; Cui X; Lin Y; Li X
    Front Cell Infect Microbiol; 2023; 13():1178590. PubMed ID: 37207192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
    Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
    Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.
    Shahzad M; Chaudhary SG; Zafar MU; Hassan MA; Hussain A; Ali F; Anwar I; Ahmed M; Ahmed N; Khurana S; Rauf MA; Anwar F; Hematti P; Callander NS; Abhyankar SH; McGuirk JP; Mushtaq MU
    Transpl Infect Dis; 2022 Apr; 24(2):e13792. PubMed ID: 35030267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying risk factors for severe omicron infection in allogeneic hematopoietic stem cell transplant recipients with hematologic malignancies.
    Li Z; Wang L; Zheng Q; Xu T; Yang K; Wang X; Wen X; Zhang C; Wang J; Song Y; Zhao Y; Zheng X; Wu T
    Cancer Rep (Hoboken); 2024 Jun; 7(6):e2103. PubMed ID: 39031740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia.
    Oltolini C; Acerbis A; Orofino G; Racca S; Noviello M; Dispinseri S; Clementi N; Piemontese S; Xue E; Giglio F; Lupo Stanghellini MT; Diral E; Bruno A; Tassi E; Beretta V; Marzinotto I; Scarlatti G; Lampasona V; Ardemagni A; Sampaolo M; Bonini C; Corti C; Peccatori J; Castagna A; Ciceri F; Greco R
    Front Immunol; 2023; 14():1184956. PubMed ID: 37287986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study.
    Averbuch D; de la Camara R; Tridello G; Knelange NS; Bykova TA; Ifversen M; Dobsinska V; Ayas M; Hamidieh AA; Pichler H; Perez-Martinez A; Cesaro S; Sundin M; Badell I; Bader P; Johansson JE; Mirci-Danicar O; Sedlacek P; Paillard C; Gibson B; Lawson S; Kroeger N; Corbacioglu S; Mikulska M; Piñana JL; Styczynski J; Ljungman P
    Bone Marrow Transplant; 2023 May; 58(5):558-566. PubMed ID: 36849806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.
    Einarsdottir S; Martner A; Waldenström J; Nicklasson M; Ringlander J; Arabpour M; Törnell A; Wiktorin HG; Nilsson S; Bittar R; Nilsson M; Lisak M; Veje M; Friman V; Al-Dury S; Bergström T; Ljungman P; Brune M; Hellstrand K; Lagging M
    Blood Adv; 2022 May; 6(9):2723-2730. PubMed ID: 35286374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.